z-logo
Premium
[ 3 H]‐5‐carboxamidotryptamine labels 5‐HT 1D binding sites in bovine substantia nigra
Author(s) -
Nowak Henry P.,
Mahle Cathy D.,
Yocca Frank D.
Publication year - 1993
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.1993.tb13750.x
Subject(s) - substantia nigra , radioligand , binding site , radioligand assay , 5 ht receptor , chemistry , receptor , stereochemistry , serotonin , biochemistry , biophysics , microbiology and biotechnology , biology , endocrinology , dopamine , dopaminergic
1 [ 3 H]‐5‐hydroxytryptamine (5‐HT) has been shown to radiolabel at least five types of 5‐HT binding sites in mammalian brain tissue, 5‐HT 1A , 5‐HT 1B , 5‐HT 1C , 5‐HT 1D and 5‐HT 1E (Frazer et al. , 1990). Selective masking of 5‐HT 1A and 5‐HT 1C receptors, has uncovered binding sites which display both high (5‐HT 1D ) and low (5‐HT 1E ) affinity for 5‐carboxamidotryptamine (5‐CT). By utilizing [ 3 H]‐5‐CT we have eliminated a portion of the complex binding (5‐HT 1E ) seen when [ 3 H]‐5‐HT is used as a radioligand. 2 [ 3 H]‐5‐CT binding to 5‐HT 1D sites in bovine substantia nigra was rapid, reversible and saturable, displaying high affinity ( K d = 0.38 ± 0.04 n m ) and low non‐specific binding (> 90% specific binding). 3 In bovine substantia nigra, [ 3 H]‐5‐CT labelled an equivalent number of binding sites to [ 3 H]‐5‐CT (403 ± 18 and 362 ± 20 fmol mg −1 protein, respectively) and binding was sensitive to guanine nucleotides. 4 A linear correlation ( r 2 = 0.99) existed between the potency of compounds to displace [ 3 H]‐5‐HT and [ 3 H]‐5‐CT in bovine substantia nigra. 5 Therefore, [ 3 H]‐5‐CT is a novel radioligand for the examination of 5‐HT 1 ‐like binding sites, which under proper experimental conditions can be used to radiolabel selectively 5‐HT 1D ‐like binding sites.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here